REGISTERED
on 09 Apr 2024
Last Applicant/ Owned by
NL-1098 XH AMSTERDAM
BX
Serial Number
79363427 filed on 11th Jan 2023
Registration Number
7349628 registered on 09th Apr 2024
Correspondent Address
Douglas T. Johnson Miller & Martin PLLC
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
ARCHIVECT
Scientific and medical research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Scientific and medical research and product development in the field of pharmaceutics Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of me Read More
Classification Information
Class [044]
Medical, Beauty & Agricultural Services
Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics
First Use Date in General
11th 000101
First Use Date in Commerce
11th 000101
Class [042]
Computer & Software Services & Scientific Services
Scientific and medical research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Scientific and medical research and product development in the field of pharmaceutics
First Use Date in General
11th 000101
First Use Date in Commerce
11th 000101
Class [005]
Pharmaceutical Products
Viral systems comprised of viral vectors combined with antibodies; gene therapy systems comprised of viral vectors combined with antibodies; nucleic acid delivery systems being therapeutic agents for delivery to human tissue namely viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for the treatment neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; clinical medical reagents for use in nucleic acid-based therapy, cell therapy, pharmaceutical preparations, prophylaxis products preparations and other pharmaceutical products preparations and other pharmaceutical products preparations for use in nucleic acid-based therapy, gene therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases
First Use Date in General
11th 000101
First Use Date in Commerce
11th 000101
Mark Details
Serial Number
No 79363427
Mark Type
No Service Mark
Attorney Docket Number
No 19250-0463
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 09th Apr 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 09th Apr 2024 | REGISTERED-PRINCIPAL REGISTER |
| 23rd Jan 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 23rd Jan 2024 | PUBLISHED FOR OPPOSITION |
| 22nd Jan 2024 | NOTIFICATION PROCESSED BY IB |
| 03rd Jan 2024 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| 03rd Jan 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 03rd Jan 2024 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| 18th Dec 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 12th Dec 2023 | EXAMINER'S AMENDMENT ENTERED |